Cardiology

An overview of the journey and significant events of 2023 that have catapulted semaglutide from a type 2 diabetes agent to the topic of discussions among circles across healthcare and beyond.

Our November 2023 month in review for cardiology features highlights from AHA 2023, new atrial fibrillation guidelines, a pair of historic approvals from the FDA, and more!

Released on Nov. 30, 2023, the new AFib guidance from the ACC/AHA contains update recommendations for early and aggressive rhythm control, wearables, left atrial appendage occlusion, and more.

A trial randomizing brain-dead donor hearts to levothyroxine administration or saline has returned results challenging conventional wisdom on the topic, with data indicating thyroid hormone administration may provide no significant benefit.

Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.

Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.

Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.

This cardiology case report from Brady Pregerson, MD, features a man in his late 50s presenting with 3 days of episodic chest pain. Can you determine the correct diagnosis?

The FDA has approved the second renal denervation device in the agency's history with the approval of Medtronic's Symplicity Spyral system.

This case report from Brady Pregerson, MD, features a man in his early 70s presenting to the hospital with palpitations for the past 2 hours that started while playing a round of golf. Can you determine the most likely rhythm?

At the 14-year follow-up, ADHD medication use was associated with a 4% increased risk of cardiovascular diseases.

Bayer has announced the IDMC for OCEANIC-AF trial has recommended the trial be discontinued as a result of inferior efficacy.

Ahmad Masri, MD, MS, discusses new acoramidis data from the ATTRibute-CM trial at AHA 2023.

A post hoc analysis of the SCORED trial suggested the clinical benefit of sotagliflozin on heart failure and MACE-related outcomes in as early as 3 months in a high-risk population.

Presented at AHA 2023, new analyses of VOYAGER PAD suggest the benefit of rivaroxaban plus aspirin for high-risk and complex populations with PAD.

A group of 13 leading experts provides their perspectives on the top news in cardiovascular medicine from 2023, with responses ranging from novel approvals to new semaglutide data to gene therapy and more.

Christian Ruff, MD, MPH discusses results from the phase 2 AZALEA-TIMI 71 trial, the need for new antithrombotic therapies, and the net clinical benefit outcome of abelacimab for AF.

Viet Le, DMSc, PA-C, discusses early data from the Target-D trial and how this might influence the way he interprets the findings from other vitamin D supplementation studies.

In an interview at AHA 2023, Deepak Bhatt, MD, MPH, discusses recent advancements in cardiovascular risk management, with a focus on the evolving recognition of inflammation, Lp(a), and obesity as modifiable risk factors.

Ahmad Masri, MD, MS, discusses a study he led examining disparities in time to diagnosis of hypertrophic cardiomyopathy using Medicare claims data.

An artificial intelligence can detect increased fluid in lungs by simply hearing voice changes over time—and the increased fluid in lungs can be a sign of heart failure.

Compared to their usual diet, participants placed in the low sodium diet group—required to keep their sodium intake to 500 mg daily—had their blood pressure reduced by 6 mm Hg.

FDA approved sotaglifozin (INPEFA®) on May 26, 2023, to treat heart failure. Also, a phase 3 trial shows the clinical benefits of the drug by the 3-month mark.

Results of ARIES-HM3 demonstrate use of aspirin was associated with an increased rate of major bleeding following HeartMate 3 implantation.

In this episode, hosts sit down between sessions at AHA 2023 to discuss the landmark SELECT trial, their interpretation of the data, and its implications for care moving forward. Later in the episode, hosts break down the DAPA-MI trial.